We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Test for Cardiac Protein Diagnoses Heart Attack

By LabMedica International staff writers
Posted on 17 Nov 2011
Print article
A novel blood test for a cardiac biomarker has been used to determine whether a patient has had a heart attack.

The test measures a large protein known as cardiac myosin binding protein-C (cMyBP-C), which is released into the blood following a cardiac event.

Scientists at Loyola University Chicago (Maywood, IL, USA) quantified plasma levels of cMyBP-C by a sandwich enzyme-linked immunosorbent assay (ELISA) using capture monoclonal anti-cMyBP-C, E7 and a detection rabbit polyclonal antibody anti-cMyBP-CC0–C1. Plasma cardiac troponin (cTnI) levels were also measured by a commercial sandwich ELISA. To determine the sensitivity of the sandwich ELISA for cMyBP-C, the investigators defined the limit of detection values and quantification for lower and upper limits. The values of lower limit of quantification and upper limit of quantification were 0.02 ng/ml and 2,053 ng/ml, respectively.

Plasma samples were collected from 16 myocardial infarction) MI) patients and 11 normal healthy controls. Importantly, cMyBP-C and cTnI levels in the plasma samples of healthy controls were very low, 0.95 ± 0.34 ng/mL and 0.238 ± 0.07 ng/mL, respectively. Strikingly, the concentration of cMyBP-C in the plasma of MI patients was significantly increased to 227 ± 50 ng/mL, compared to controls and greater than plasma cTnI levels at 30 ± 9 ng/mL. The anti-cMyBP-C, E7 monoclonal antibody used in this study is a product Santa Cruz Biotechnology (Santa Cruz, CA, USA). The human cardiac troponin assay was produced by Calbiotech (San Diego, CA, USA).


Sakthivel Sadayappan, PhD, senior author of the study said, "This potentially could become the basis for a new test, used in conjunction with other blood tests, to help diagnose heart attacks. This is the beginning. A lot of additional studies will be necessary to establish cMyBP-C as a true biomarker for heart attacks." The authors concluded that future studies would determine the time course of release, peak concentrations, and half-life in the circulatory system. The study was available online since September 19, 2011, in the Journal of Molecular and Cellular Cardiology.

Related Links:
Loyola University Chicago
Santa Cruz Biotechnology
Calbiotech


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.